Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
The initial courses of Lap. Hernia Masterclass will encompass commonly performed hernia procedures
The HD-550 endoscopy system has been available outside of the USA since 2019
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
This product will be manufactured at Lupin’s Nagpur facility in India
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
The Centre aims to channel the potential of traditional medicine by integrating it with technological advancements and evidence-based research
The company also plans to expand the facility
Subscribe To Our Newsletter & Stay Updated
